Skip to Content

Regencell Bioscience Holdings Limited 

Securities Class Action

  • Date:
  • 4/27/2026
  • Company Name:
  • Regencell Bioscience Holdings Limited
  • Stock Symbol:
  • RGC
  • Class Period:
  • FROM 10/28/2024 TO 10/31/2025
  • Status:
  • Filed
  • Filing Date:
  • 4/24/2026
  • Court:
  • U.S. District Court: District of Maryland

Case Finder

Locate any case using the tools below.

Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Regencell Bioscience Holdings Limited (“Regencell” or the “Company”) (NASDAQ:RGC) in The United States District Court for the District of Maryland on behalf of all persons and entities who purchased or otherwise acquired Regencell securities between October 28, 2024 and October 31, 2025, both dates inclusive (the “Class Period”). Investors have until June 23, 2026 to apply to the Court to be appointed as lead plaintiff in the lawsuit. 
 

The lawsuit alleges that Defendants made false and misleading statements and/or failed to disclose material adverse facts regarding Regencell’s business, operations, and compliance policies, including allegations that: (i) Regencell was vulnerable and/or subject to market manipulation; (ii) the resulting volatility in the market for the Company’s ordinary shares exposed Regencell’s investors to significant financial risk; and (iii) all the foregoing subjected Regencell to a heightened risk of regulatory and/or governmental scrutiny and enforcement action, as well as significant legal, monetary, and reputational harm. 

If you purchased or otherwise acquired Regencell shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Melissa Fortunato by email at investigations@bespc.com, by telephone at (212) 355-4648, or by filling out the form below.  There is no cost or obligation to you.
Contact Instructions
Please contact Brandon Walker or Melissa Fortunato by email at investigations@bespc.com with any questions regarding the case.
The individual or institution below (“Plaintiff”) has reviewed and agrees to the Bragar Eagel & Squire, P.C. (“BESPC”) retainer agreement and authorizes BESPC to prosecute an action on Plaintiff’s behalf under the federal securities laws or applicable state laws to recover damages on behalf of investors in Regencell Bioscience Holdings Limited. BESPC will prosecute the action on a full contingency basis and will forward all costs and expenses.
 

Case Finder

Locate any case using the tools below.

You may share a link to this page on any of the sites listed below or send link via email: